Metraipolis › archive › dc_e974c62ef459

AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model — Europe PMC PMID:41486111

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41486111
DOI
10.1186/s12929-[numero omesso]-z
License (as archived)
solo-consultazione
Archived
2026-11-07T01:59:31.801Z
SHA-256 of the archived text
0698c56130ab48d12fbceaf1a01bb0b329ba72cda71632368610de8e0b4f7949
Stable URL of this page
https://metraipolis.com/documento/dc_e974c62ef459

How to cite

AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model — Europe PMC PMID:41486111 — Europe PMC (en), https://europepmc.org/article/MED/41486111 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e974c62ef459 (Metraipolis archive dc_e974c62ef459, sha256 0698c56130ab48d12fbceaf1a01bb0b329ba72cda71632368610de8e0b4f7949)
BibTeX
@misc{dce974c62ef459,
  title = {AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model — Europe PMC PMID:41486111},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41486111},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e974c62ef459; sha256 0698c56130ab48d12fbceaf1a01bb0b329ba72cda71632368610de8e0b4f7949},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41486111. Agents can read the archived copy with the MCP tool read_document.